Reuters logo
Novo presents liraglutide data showing 8 pct weight loss
May 16, 2014 / 6:27 AM / 3 years ago

Novo presents liraglutide data showing 8 pct weight loss

May 16 (Reuters) - Danish drugmaker Novo Nordisk said results from the largest trial of its experimental obesity treatment liraglutide showed an 8 percent weight loss compared to 2.6 percent with placebo after a year of treatment.

The data is being presented on Friday at the annual Congress of the American Association of Clinical Endocrinologists.

The study involved 3 mg of liraglutide - a drug which is already on sale as a treatment for type-2 diabetes under the brand name Victoza.

Novo submitted liraglutide 3 mg for regulatory approval for chronic weight management in adults with obesity in December. (Reporting by Ben Hirschler; Editing by Mark Potter)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below